Ozempic provide will proceed to be restricted till the tip of subsequent 12 months, in keeping with the newest recommendation from Novo Nordisk, Ozempic’s provider.
The Therapeutic Items Administration (TGA) stated Novo Nordisk has suggested that they’re persevering with to extend manufacturing capability, however it might take time to construct provide ranges to satisfy international and Australian demand.
The TGA stated the semaglutide product is authorised for the administration of sort 2 diabetes not adequately managed by different medicines, along with food plan and train. A separate semaglutide product, Wegovy, is authorised to assist with power weight administration.
Diabetes Australia understands the numerous issues of Australians dwelling with sort 2 diabetes concerning the ongoing Ozempic scarcity and can proceed to advocate for prioritised entry for folks dwelling with diabetes.
Diabetes Australia has advocated for the TGA to analyze the shortages of plenty of diabetes-related medicines and merchandise lately and redouble efforts to make sure Australians might be assured that provide chains are adequate to satisfy their wants.
The TGA has requested well being professionals to:
- think about the continued scarcity when prescribing Ozempic, inform sufferers that provide is anticipated to be restricted in 2025, and talk about various remedies when sufferers are unable to entry the medication.
- prescribe and provide each Ozempic and Wegovy in keeping with their authorised indications.
Details about the Ozempic scarcity is obtainable from the TGA web site.
